TUBA4A

TUBA4A encodes an α-tubulin isotype that incorporates into the microtubule network and is required for its stability and capacity to repolymerize, with disease-associated missense variants impairing these functions in cellular and patient-derived assays (PMID:25374358, PMID:38884572). Its abundance is post-translationally controlled: excess tubulin-folding cofactor B (TBCB) drives depolymerization and degradation of TUBA4A through a miR-1825/TBCB/TUBA4A axis that is dysregulated in ALS patient cortex and produces motor axon defects in vivo (PMID:30030593). Loss of TUBA4A function is conserved across species — zebrafish orthologue knockdown causes dose-dependent motor axonopathy rescuable by human wild-type mRNA, and additionally shifts the tubulin post-translational modification landscape including acetylation, detyrosination, and polyglutamylation (PMID:38463699). Pathogenicity operates through distinct mechanisms tied to mutation position: C-terminal ALS-associated variants act dominant-negatively by destabilizing microtubules (PMID:25374358), whereas an N-terminal frameshift produces no detectable protein and reduces total TUBA4A, indicating haploinsufficiency (PMID:35327632). A subset of missense variants instead cause cytoplasmic TUBA4A aggregation that colocalizes with ubiquitin and is accompanied by autophagic, proteinopathic muscle pathology (PMID:38413182, PMID:41678358). These functional and structural perturbations collectively link TUBA4A dysfunction to a spectrum of disease spanning ALS/FTD, spastic ataxia, and primary myopathy, with domain specificity shaping the affected cell type and clinical pattern (PMID:34169147, PMID:41678358, PMID:41889878).

1. 2014 High

   Established that ALS-associated TUBA4A variants are not benign polymorphisms but functionally compromise the microtubule cytoskeleton, providing the first mechanistic link between this α-tubulin and motor neuron disease.

   Evidence Microtubule repolymerization assays in cells expressing multiple ALS-associated mutant TUBA4A variants

   PMID:25374358

   Open questions at the time

   • Did not resolve whether the defect is dominant-negative versus loss-of-function
   • No in vivo or patient-tissue confirmation in this study
2. 2018 High

   Answered how TUBA4A protein levels are controlled by identifying TBCB as a negative regulator whose excess degrades TUBA4A, embedding TUBA4A in a miR-1825/TBCB regulatory axis relevant to ALS.

   Evidence Transcriptomic/proteomic analysis with protein validation in ALS patient cortex and an in vivo motor-axon model

   PMID:30030593

   Open questions at the time

   • Structural basis of TBCB-driven TUBA4A degradation not defined
   • Does not establish whether this axis is causal or secondary in sporadic ALS
3. 2021 Medium

   Extended TUBA4A dysfunction beyond ALS to FTD and introduced the idea that mutation position correlates with phenotype, with FTD variants clustering N-terminally.

   Evidence Immunoblotting and microtubule repolymerization assay for an FTD-associated variant

   PMID:34169147

   Open questions at the time

   • Single variant analyzed
   • Domain-phenotype correlation based on positional clustering rather than direct mechanistic comparison
4. 2022 Medium

   Distinguished a haploinsufficiency mechanism for N-terminal mutations by showing a frameshift variant yields no detectable protein and lowers total TUBA4A, contrasting with the dominant-negative model for C-terminal variants.

   Evidence qPCR, immunoblotting, and immunohistochemistry of patient material

   PMID:35327632

   Open questions at the time

   • Single case study
   • Does not test whether reduced dosage alone reproduces neuronal phenotypes
5. 2023 Low

   Proposed atomic-level explanations for variant pathogenicity, predicting impaired GTP binding, destabilized polymerization, and increased aggregation propensity for specific mutations.

   Evidence Molecular dynamics simulation and docking of ALS-associated mutations

   PMID:36747013

   Open questions at the time

   • Computational prediction with no experimental validation
   • Aggregation propensity predicted, not measured
   • GTP-binding defect not biochemically confirmed
6. 2024 High

   Provided in vivo loss-of-function evidence and connected TUBA4A to tubulin PTM homeostasis, showing knockdown causes motor axonopathy rescuable by human wild-type mRNA and alters acetylation, detyrosination, and polyglutamylation.

   Evidence Antisense morpholino knockdown in zebrafish with mRNA rescue, motor axon imaging, behavior assay, and antibody-based PTM detection

   PMID:38463699

   Open questions at the time

   • Mechanism linking TUBA4A loss to altered PTMs not defined
   • Morpholino-based knockdown not complemented by stable genetic null
7. 2024 Medium

   Identified a proteinopathy mechanism in which a TUBA4A missense variant aggregates and colocalizes with ubiquitin, linking TUBA4A to myopathy with rimmed vacuoles and broadening the phenotypic spectrum to muscle.

   Evidence Overexpression in a cellular model with immunofluorescence and immunohistochemistry of patient muscle biopsy

   PMID:38413182

   Open questions at the time

   • Aggregation shown by overexpression, not at endogenous levels
   • Single variant and single lab
8. 2024 Medium

   Confirmed pathogenicity of distinct missense variants in disease-relevant patient cells by demonstrating altered microtubule organization and dynamics.

   Evidence Microtubule organization/dynamics assays in patient-derived fibroblasts for three independent variants

   PMID:38884572

   Open questions at the time

   • Mechanistic basis (dynamics defect vs. dosage) not disentangled per variant
   • Single study
9. 2025 Medium

   Established TUBA4A as a primary myopathy gene and demonstrated domain specificity, showing variants cause protein accumulation with autophagic proteinopathy and differentially impact microtubule dynamics depending on the affected domain.

   Evidence Immunohistochemistry of patient muscle biopsies with in silico and in vitro microtubule dynamics assays across multiple variants

   PMID:41678358

   Open questions at the time

   • Causal link between accumulation and autophagy not resolved
   • Domain-to-phenotype mapping correlative
10. 2026 Medium

    Demonstrated cell-type-selective consequences of a TUBA4A mutation in a mammalian model, with ataxia, Purkinje degeneration, and muscle defects but no motor neuron degeneration.

    Evidence ENU screen with CRISPR knock-in confirmation of Tuba4a p.Gln176Pro, neuropathological and behavioral analysis in mouse (preprint)

    PMID:41889878

    Open questions at the time

    • Preprint not yet peer-reviewed
    • Molecular basis of cell-type selectivity unexplained
    • Single mutation modeled

• It remains unresolved why TUBA4A variants of differing position and biochemical effect produce divergent tissue tropism (motor neuron, cortical, cerebellar, muscle), and how dominant-negative, haploinsufficiency, and aggregation mechanisms are selected in each context.
• No unifying model linking mutation domain to cell-type vulnerability
• No structural data on mutant tubulin in assembled microtubules
• Relationship between altered PTMs and disease phenotype undefined